Interestingly, the c-Met inhibitor ARQ-197 limits MM cell proliferation in vitro and in a JJN3-NSG xenograft model, and this parallels with a reduced number of osteolytic lesions [45]. The gene discussed is MET; the disease is Miyoshi myopathy.